Lipid Control and Medical Costs Among Patients With and Without Established Atherosclerotic Cardiovascular Disease Followed in a Brazilian Private Healthcare System
References
- Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vascular Medicine. 1998; 3(3):225–229. DOI: 10.1177/1358836X9800300309
- Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349(9064):1498–1504. DOI: 10.1016/S0140-6736(96)07492-2
- Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. American Heart Journal. 2006; 151(4):
786 e1–10. DOI: 10.1016/j.ahj.2005.11.004 - Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11; 295(2):180–189.
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7; 42(34):3227–3337. DOI: 10.1093/eurheartj/ehab484
- Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7; 42(14):1289–1367. DOI: 10.1093/eurheartj/ehaa575
- Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14; 41(3):407–477. DOI: 10.1093/eurheartj/ehz425
- Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Mar 21; 135(12):e686–e725. DOI: 10.1161/CIR.0000000000000470
- Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 7; 395(10226):795–808. DOI: 10.1016/S0140-6736(19)32008-2
- Berwanger O, Piva e Mattos LA, Martin JF, Lopes RD, Figueiredo EL, Magnoni D, et al. Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study. Arquivos Brasileiros de Cardiologia. 2013; 100(3):212–220. DOI: 10.5935/abc.20130062
- Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R, et al. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). Eur Heart J. 2016 Jan 7; 37(2):152–160. Epub 2015 Sep 1. DOI: 10.1093/eurheartj/ehv437
- Olesen KKW, Gyldenkerne C, Thim T, Thomsen RW, Maeng M. Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry. BMJ Open Diabetes Res Care. 2021 Jan; 9(1):
e001803 . DOI: 10.1136/bmjdrc-2020-001803 - Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ, Sposito AC, et al. V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis]. Arq Bras Cardiol. 2013 Oct; 101(4 Suppl 1):1–20. Portuguese. DOI: 10.5935/abc.2013S010
- Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A Neto, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017 Jul; 109(2 Supl 1):1–76. Portuguese. DOI: 10.5935/abc.20170121
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1; 41(1):111–188. DOI: 10.1093/eurheartj/ehz455
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18; 139(25):e1082–e1143. Epub 2018 Nov 10. DOI: 10.1161/CIR.0000000000000624
- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction The American Heart Association’s Strategic Impact Goal Through 2020. Circulation 2010; 121:586–613. DOI: 10.1161/CIRCULATIONAHA.109.192703
- NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020 Jun; 582(7810):73–77.
- De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D; EUROASPIRE V collaborators; Writing Committee; Scientific Steering/Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk). Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019 Jun; 285:135–146. DOI: 10.1016/j.atherosclerosis.2019.03.014
- Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018; 25(10):1087–1094. DOI: 10.1177/2047487318777079
- Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021; 6(9):1–9. DOI: 10.1001/jamacardio.2021.1810
- de Barros E Silva PGM, do Nascimento CT, Pedrosa RP, Nakazone MA, do Nascimento MU, de Araújo Melo L, Júnior OLS, et al. Primary results of the brazilian registry of atherothrombotic disease (NEAT). Sci Rep. 2024 Feb 20; 14(1):
4222 . DOI: 10.1038/s41598-024-54516-9 - Silva PGMBE, Berwanger O, Precoma DB, Cavalcante MA, Vilela-Martin JF, Figueiredo EL, et al. Evaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT). Arq Bras Cardiol. 2021 Jan; 116(1):108–116. English, Portuguese. DOI: 10.36660/abc.20190885
- Pencina MJ, Pencina KM, Lloyd-Jones D, Catapano AL, Thanassoulis G, Sniderman AD. The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation. 2020 Sep; 142(9):827–837. DOI: 10.1161/CIRCULATIONAHA.120.045851
- McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc. 2019 Dec 17; 8(24):
e013225 . DOI: 10.1161/JAHA.119.013225 - Jasani R, Ahmad Z, Schneider R, Tujardon C, Basit M, Khera A. Applying an LDL-C threshold-based approach to identify individuals with familial hypercholesterolemia. J Clin Lipidol. 2022 Jul–Aug; 16(4):508–515. DOI: 10.1016/j.jacl.2022.04.001
- Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C ≥ 190 mg/dL in a large health care system. Am J Prev Cardiol. 2020 May 1; 1:
100002 . DOI: 10.1016/j.ajpc.2020.100002 - Porter ME. What is value in health care? N Engl J Med. 2010 Dec 23; 363(26):2477–2481. DOI: 10.1056/NEJMp1011024
- Teisberg E, Wallace S, O’Hara S. Defining and Implementing Value-Based Health Care: A Strategic Framework. Acad Med. 2020 May; 95(5):682–685. DOI: 10.1097/ACM.0000000000003122
DOI: https://doi.org/10.5334/gh.1345 | Journal eISSN: 2211-8179
Language: English
Submitted on: Mar 11, 2024
Accepted on: Jul 24, 2024
Published on: Aug 14, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2024 Pedro Gabriel Melo de Barros e Silva, Henry Szneider, Diego Ribeiro Garcia, Valter Furlan, Renato Delascio Lopes, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.